GlaxoSmithKline Short Interest Ratio and Short Volume

+0.44 (+1.16 %)
(As of 05/7/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume3.00 million shs
Average Volume5.76 million shs
Market Capitalization$103.26 billion
P/E Ratio11.80
Dividend Yield6.65%

Short Interest

GlaxoSmithKline (NYSE:GSK) Short Interest Data

Current Short Volume28,200,000 shares
Previous Short Volume27,670,000 shares
Change Vs. Previous Month+1.92%
Dollar Volume Sold Short$1.02 billion
Short Interest Ratio / Days to Cover4.4
Last Record DateApril, 15 2021
Outstanding Shares2,692,595,000 shares
Percentage of Shares Shorted1.05%
Today's Trading Volume3,004,116 shares
Average Trading Volume5,757,572 shares
Today's Volume Vs. Average-47.82%

Short Interest Over Time

GlaxoSmithKline (NYSE:GSK) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
4/15/202128,200,000 shares $1.02 billion +1.9%N/A4.4$36.13
3/31/202127,670,000 shares $1.01 billion +17.6%N/A4.6$36.37
3/15/202123,520,000 shares $835.90 million +14.7%N/A4.1$35.54
2/26/202120,500,000 shares $704.79 million +5.6%N/A3.6$34.38
2/12/202119,410,000 shares $685.56 million +37.1%N/A3.6$35.32
1/29/202114,160,000 shares $538.50 million +3.1%N/A2.7$38.03
1/15/202113,730,000 shares $523.94 million +5.1%N/A2.8$38.16
12/31/202013,060,000 shares $483.74 million +8.7%N/A2.6$37.04
12/15/202012,010,000 shares $442.33 million +6.5%N/A2.5$36.83
11/30/202011,280,000 shares $418.15 million -18.3%N/A2.4$37.07
11/15/202013,800,000 shares $528.54 million +29.1%N/A3.1$38.30
10/30/202010,690,000 shares $363.03 million -5.7%N/A2.8$33.96
10/15/202011,340,000 shares $421.96 million +2.4%N/A3.4$37.21
9/30/202011,080,000 shares $417.05 million -2.7%N/A3.6$37.64
9/15/202011,390,000 shares $447.29 million +14.1%N/A4$39.27
8/31/20209,980,000 shares $395.21 million +1.6%N/A3.4$39.60
8/14/20209,820,000 shares $398.20 million -5.2%N/A3.3$40.55
7/31/202010,360,000 shares $417.72 million +2.5%N/A3.3$40.32
7/15/202010,110,000 shares $424.11 million +6.0%N/A3.2$41.95
6/30/20209,540,000 shares $389.14 million +19.1%N/A2.9$40.79
6/15/20208,010,000 shares $326.17 million -7.4%N/A2.1$40.72
5/29/20208,650,000 shares $362.61 million -22.8%N/A1.9$41.92
5/15/202011,200,000 shares $458.19 million +11.3%N/A2.2$40.91
4/30/202010,060,000 shares $423.22 million +5.5%N/A1.9$42.07
4/15/20209,540,000 shares $379.88 million -5.0%N/A1.8$39.82

GlaxoSmithKline (NYSE:GSK) Short Interest FAQ

speech bubbles
speech bubbles

What is GlaxoSmithKline's current short interest?

Short interest is the volume of GlaxoSmithKline shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 28,200,000 shares of GSK short.

What is a good short interest ratio for GlaxoSmithKline?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GlaxoSmithKline currently has a short interest ratio of 4.0.

Is GlaxoSmithKline's short interest increasing or decreasing?

GlaxoSmithKline saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 28,200,000 shares, an increase of 1.9% from the previous total of 27,670,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does GlaxoSmithKline's short interest compare to its competitors?

0.00% of GlaxoSmithKline's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to GlaxoSmithKline: Roche Holding AG (0.00%), Pfizer Inc. (0.00%), Abbott Laboratories (0.00%), AbbVie Inc. (0.00%), Novartis AG (0.31%), Merck & Co., Inc. (0.83%), Eli Lilly and Company (0.80%), Novo Nordisk A/S (0.24%), Bristol-Myers Squibb (0.00%), and AstraZeneca PLC (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Analog Devices, Inc. ($5.85 billion), Aon plc ($5.61 billion), Charter Communications, Inc. ($5.44 billion), Snap Inc. ($3.49 billion), Airbnb, Inc. ($3.35 billion), Peloton Interactive, Inc. ($2.53 billion), ViacomCBS Inc. ($2.48 billion), Expedia Group, Inc. ($2.39 billion), The Kroger Co. ($2.26 billion), and Nuance Communications, Inc. ($2.18 billion). View all of the most shorted stocks.

What does it mean to sell short GlaxoSmithKline stock?

Short selling GSK is an investing strategy that aims to generate trading profit from GlaxoSmithKline as its price is falling. GlaxoSmithKline's stock is trading up $0.44 today. To short GlaxoSmithKline stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that GlaxoSmithKline will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against GlaxoSmithKline?

A short squeeze for GlaxoSmithKline occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GSK, which in turn drives the price of the stock up even further.

How often is GlaxoSmithKline's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GSK, twice per month. The most recent reporting period available is April, 15 2021.

This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.